In this abstract presentation, Dr. Steve Coutre discusses the use of 420 mg of single-agent ibrutinib to induce durable responses including complete responses (CRs) in patients with chronic lymphocytic leukemia (CLL) following long-term treatment.
A continuing education program is offered as a supplement to this webcast at the following location:
http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP
© 2015 Imedex, LLC.